Mavacamten for obstructive hypertrophic cardiomyopathy
Part of Heart & circulation clinical trials.
This study tests whether mavacamten, a medication that may help the heart use energy better, can improve symptoms in people with obstructive hypertrophic cardiomyopathy. It aims to see if this drug helps with chest pain and shortness of breath, and improve overall heart function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You need a confirmed diagnosis of obstructive hypertrophic cardiomyopathy (oHCM), which is a type of heart muscle disease causing blockage of blood flow.
- You must meet specific heart measurement criteria (a pressure gradient of 50 mmHg or higher) and be in a certain symptom class (NYHA II or III) with a preserved heart pumping function (EF ≥ 55%).
- You must not have had a septal reduction procedure (surgery or alcohol ablation) in the last 6 months.
- You must not have conditions that mimic HCM (like amyloidosis or Fabry disease) or any reason you can't take mavacamten or have an MRI.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if mavacamten can help people with hypertrophic cardiomyopathy (HCM) who have obstruction in the middle or tip of the heart (not the usual outflow tract). You may join if you have symptoms like chest pain or shortness of breath and a pressure gradient above 30 mmHg in these areas.
This study looks at how a drug called mavacamten, which relaxes the heart muscle, works in people with obstructive hypertrophic cardiomyopathy. It uses genetic testing to try to predict who will respond best to the drug.
This study looks at how well mavacamten works in real life for adults with obstructive hypertrophic cardiomyopathy, a condition where the heart muscle is thickened and blocks blood flow. It may help improve symptoms like shortness of breath or chest pain.
This study tests whether the drug mavacamten (Camzyos) improves blood flow in the heart's small vessels for people with obstructive hypertrophic cardiomyopathy. You will take mavacamten as prescribed and have a PET/CT scan to measure your heart's blood flow reserve.
This study looks at adults with a heart condition called obstructive hypertrophic cardiomyopathy. It tracks what happens after they start taking the medicine mavacamten, to learn more about its effects and how it works in real life.
This study looks at how mavacamten (a heart medication) works for people with obstructive hypertrophic cardiomyopathy (HCM)—a condition where heart muscle becomes too thick. Researchers will review medical records and ask patients about their experiences with the treatment.
Hear when a new Hypertrophic Cardiomyopathy (HCM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.